DMIIDrugs Made In America Acquisition II Corp.
$10.19
$10.19
$9.8752 weeks$10.33
Price
End-of-day closes, not the intraday tick.
The five questions
1 of 5 availableOnly one of the five can be answered for DMII today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Good
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?not enough filed
P/En/a
Market value$649.1M
1 yearn/a
5 yearsn/a
What the company said
The company's own words from its current reports to the SEC, newest first
- Apr 28, 2026As previously disclosed, on November 17, 2025, Drugs Made in America Acquisition II Corp. (the “Company”) appointed Saleem Elmasri as Chief Financial Officer of the Company and entered into a Master Services Agreement (the “Consulting Agreement”) with Titan Advisory Services LLC for the provision of such principal …Material agreement entered · Form 8-K
- Apr 3, 2026As previously disclosed, on March 11, 2026, Drugs Made In America Acquisition II Corp. (the “Company”) issued an unsecured convertible note (the “Bridge Note”) to Alpha Multi Family Office (the “Investor”) in the principal amount of $150,000 (the “Bridge Loan”)Material agreement entered · Form 8-K
- Mar 17, 2026On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “Company”) issued an unsecured convertible note (the “Bridge Note”) to Alpha Multi Family Office (the “Investor”) in the principal amount of $150,000 (the “Bridge Loan”)Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Shell Companies
The closest names by size in the same industry